Pioneering Medical Innovations
Ocular reported Q2 2026 results, confirming the AXPAXLI wet AMD NDA submission remains on track for Q4 2026 following a positive Type C meeting with the FDA.
Ocular reported Q1 2026 results, with a cash balance of $666.7 million and expected runway into 2028, following the positive SOL-1 readout.
Imperative Care announced $100 million in financing to support continued growth and innovation in thromboembolic disease care.
Axtria and Kedaara Capital completed a $240 million transaction combining secondary investment and a company-sponsored share buyback, one of the industry’s largest employee-centric liquidity events.
Kandu Health and Neurolutions merged to form Kandu, Inc., combining brain-computer interface technology with personalized telehealth for stroke recovery, and completed the first close of a $30 million financing co-led by Ally Bridge Group and AMED Ventures.
Ocular reported Q3 2024 results, highlighting progress in the SOL-1 and SOL-R registrational trials of AXPAXLI in wet AMD and a cash balance of $427.2 million expected to fund operations into 2028.
The company completed the initial closing of a Series E round of up to $150 million and named Shacey Petrovic Vice Chair of its Board of Directors.
Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for
BEDFORD, Mass., April 09, 2024 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of
Leadership Appointments Move Ocular Towards Being a Leader in Retinal Care Screening Underway in AXPAXLI™ Phase 3 SOL-1 Trial for Wet AMD